AVADEL PHARMACEUTICALS PLC — Director's Dealing 2025

Mar 7, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2025-03-05

Reporting Person: MCHUGH THOMAS S (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-05	Ordinary Shares	A	12600	—	Acquired	100400	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-03-05	Stock Option (Right to Buy)	$7.87	A	72000	Acquired	2030-03-06	Ordinary Shares (72000)	Direct

Footnotes

F1: Consists of a restricted share award. The restricted share award shall vest in equal annual installments on each of the first four anniversaries following the 3/5/2025 grant date.

F2: The options shall vest, if at all, in four equal increments if the volume-weighted average price of the Issuer's Ordinary Shares during any 30 calendar day period exceeds $11, $14, $17 and $19.09, respectively.